AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: https://hdl.handle.net/11055/1101
Title: Dexamethasone and Surgical-Site Infection
Authors: Corcoran Tomas B
Myles Paul S
Forbes Andrew B
Cheng Allen C
Bach Leon A
O'Loughlin Edmond
Leslie Kate
Chan Matthew TV
Story David
Short Timothy G
Martin Catherine
Coutts Pauline
Ho Kowk M
PADDI Investigators
Australian and New Zealand College of Anaesthetists Clinical Trials Network
Australasian Society for Infectious Diseases Clinical Research Network
PADDI Investigators
Australasian Society for Infectious Diseases Clinical Research Network
Keywords: Postoperative Nausea and Vomiting
Dexamethasone
Surgical Wound Infection
glucocorticoid
Diabetes
Issue Date: 6-May-2021
Source: 384(18):1731-1741
Abstract: Background: The glucocorticoid dexamethasone prevents nausea and vomiting after surgery, but there is concern that it may increase the risk of surgical-site infection. less... Methods: In this pragmatic, international, noninferiority trial, we randomly assigned 8880 adult patients who were undergoing nonurgent, noncardiac surgery of at least 2 hours' duration, with a skin incision length longer than 5 cm and a postoperative overnight hospital stay, to receive 8 mg of intravenous dexamethasone or matching placebo while under anesthesia. Randomization was stratified according to diabetes status and trial center. The primary outcome was surgical-site infection within 30 days after surgery. The prespecified noninferiority margin was 2.0 percentage points. Results: A total of 8725 participants were included in the modified intention-to-treat population (4372 in the dexamethasone group and 4353 in the placebo group), of whom 13.2% (576 in the dexamethasone group and 572 in the placebo group) had diabetes mellitus. Of the 8678 patients included in the primary analysis, surgical-site infection occurred in 8.1% (354 of 4350 patients) assigned to dexamethasone and in 9.1% (394 of 4328) assigned to placebo (risk difference adjusted for diabetes status, -0.9 percentage points; 95.6% confidence interval [CI], -2.1 to 0.3; P<0.001 for noninferiority). The results for superficial, deep, and organ-space surgical-site infections and in patients with diabetes were similar to those of the primary analysis. Postoperative nausea and vomiting in the first 24 hours after surgery occurred in 42.2% of patients in the dexamethasone group and in 53.9% in the placebo group (risk ratio, 0.78; 95% CI, 0.75 to 0.82). Hyperglycemic events in patients without diabetes occurred in 22 of 3787 (0.6%) in the dexamethasone group and in 6 of 3776 (0.2%) in the placebo group. Conclusions: Dexamethasone was noninferior to placebo with respect to the incidence of surgical-site infection within 30 days after nonurgent, noncardiac surgery. (Funded by the Australian National Health and Medical Research Council and others; PADDI Australian New Zealand Clinical Trials Registry number, ACTRN12614001226695.).
URI: http://hdl.handle.net/11055/1101
ISSN: 0028-4793
Appears in Collections:Scholarly and Clinical

Show full item record

Page view(s)

76
checked on Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.